Overview of Aminofilina

Property	Description
Active Ingredient	Theophylline ethylenediamine
Form	Solution (for injection), Tablet, Suppository
Pharmacological Class	Bronchodilator, Methylxanthine
General Purpose	Relieves bronchospasm and airflow obstruction
Origin	Synthetic, derived from xanthine

Aminofilina, known internationally as Aminophylline, is a synthetic bronchodilator medication used to help widen and relax the air passages in the lungs. It is classified as a methylxanthine, a category of drugs recognized for its systemic effects in alleviating airflow obstruction caused by the tightening of the muscles around the airways.

What Type of Drug is Aminofilina?

Aminofilina is formally classified as a bronchodilator and belongs to the methylxanthine pharmacological class, sharing a chemical kinship with natural xanthines like caffeine and theobromine. This drug is a synthetic xanthine derivative, meaning it is chemically manufactured rather than naturally occurring, and its primary function is to cause the relaxation of smooth muscle tissue. Within this class of drugs, the primary role is to treat respiratory conditions characterized by airflow obstruction. In addition to its primary function, its effects on the circulatory system also give it a secondary functional classification as a cardiotonic drug.

Composition: Why is Aminofilina a Combination Substance?

Aminofilina is not a single compound but a drug salt combination made up of the pharmacologically active moiety, theophylline, and the stabilizing agent, ethylenediamine, typically in a 2:1 molecular ratio. This unique structure is essential because the pure active component, theophylline, has poor solubility, making it difficult to formulate into effective preparations. The addition of ethylenediamine significantly increases the compound's solubility. This property allows it to be effectively administered through various routes, including parenteral (intravenous), as well as in oral tablet and rectal suppository forms.

General Purpose and Core Action of Aminofilina

The general purpose of Aminofilina is to improve breathing by addressing the physical tightening of the airways, known as bronchospasm. Its action results in bronchodilation, which is the widening of the breathing tubes, providing relief from the difficulty of breathing associated with various types of airflow obstruction. As a methylxanthine, it is utilized to relieve constricted airways. By promoting the relaxation of airway muscles, the drug allows for easier movement of air in and out of the lungs.

What side effects are possible with Aminofilina?

Possible Side Effects and Safety Information

The safety profile of Aminofilina (Aminophylline) is closely linked to the concentration of its active component, theophylline, in the blood, with severe reactions becoming more frequent when levels exceed 20 mu g/ mL. Regulatory documents categorize adverse effects primarily by the body system affected, highlighting the drug's stimulant properties.

Officially Documented Adverse Reactions by System-Organ Class

System-Organ Class (SOC)	Examples of Officially Listed Adverse Reactions
Gastrointestinal Disorders	Nausea, Vomiting, Diarrhea, Gastrointestinal Bleeding
Nervous System Disorders	Headache, Restlessness, Tremor, Seizures, Confusion
Cardiac Disorders	Palpitations, Tachycardia, Cardiac Arrhythmias, Hypotension
Metabolism and Nutrition	Hypokalemia, Hyperglycemia

Serious Adverse Reactions and Safety Constraints

Official labeling identifies severe, potentially life-threatening reactions such as Intractable Seizures, Ventricular Arrhythmias, and Cardiac Arrest. The majority of adverse reactions are classified as Incidence Not Known in regulatory documents.

Population-Specific Safety Notes

The drug is classified as having a Narrow Therapeutic Index, requiring careful consideration. Elderly patients are at a significantly greater risk of experiencing serious toxicity. Additionally, clearance is often reduced in neonates and in patients with hepatic (liver) impairment or heart failure, increasing the likelihood of adverse events.

Overdose and Emergency Response

Overdose and When to Seek Help

Aminofilina overdose is classified as a potentially life-threatening medical emergency documented to cause acute systemic toxicity, primarily centered on the Central Nervous System (CNS) and the cardiovascular system. Manifestations listed in official regulatory labeling include severe CNS excitability such as seizures and tremor, and serious cardiovascular effects like ventricular arrhythmias and hypotension. Early signs of toxicity may include pronounced gastrointestinal distress, such as persistent or repetitive vomiting and nausea.

The toxic state is formally associated with significant metabolic disturbances, including hypokalemia and hyperglycemia. The likelihood of severe toxicity increases significantly when serum theophylline concentrations exceed 20 mu mathrmg/mL.

Immediate medical help must be sought if an overdose is suspected or if signs of toxicity—such as repetitive vomiting, seizures, or a rapid, irregular heartbeat—develop. Regulatory guidance mandates that intravenous administration must be stopped immediately upon the suspicion of toxicity.

Management is documented as symptomatic and supportive, as no specific antidote is known. Officially described supportive measures include the use of activated charcoal, the correction of metabolic abnormalities, and, in severe cases, the use of dialysis (hemodialysis). Certain populations, including infants, the elderly, and patients with hepatic impairment, are noted to be at a significantly increased risk for severe, fatal outcomes.

Therapeutic Uses of Aminofilina

Aminofilina provides supportive therapeutic relief by addressing symptoms related to physical discomfort caused by difficult breathing. It is generally considered relevant across therapeutic domains where short-term symptomatic assistance is needed. This medicine is commonly used to help with wheezing, shortness of breath, and difficulty breathing caused by various lung diseases.

This medication is applied in clinical settings that involve acute or unstable symptom patterns, specifically targeting severe bronchospasm (symptoms related to heightened physiological activity) seen during conditions that include asthma exacerbations, acute worsening of Chronic Obstructive Pulmonary Disease (COPD), and specialized respiratory support for apnea of prematurity in infants. The supportive role may assist with easing the overall symptom burden during difficult episodes.

“It is often used when symptoms intensify and supportive relief is needed, supports patients during episodes of heightened discomfort.”

Aminofilina is relevant in contexts where additional symptomatic support is needed for conditions like emphysema and chronic bronchitis, where it is relevant for easing persistent airflow obstruction. This supports patients by helping them cope more steadily with symptom fluctuations, used when supportive symptom management is appropriate.

Quick Fact: Relief for Bronchospasm Aminofilina is commonly used to help manage symptoms associated with the tightening of air passages, which creates noticeable physiological strain and interference with daily functioning.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Aminofilina

The eligibility for using Aminofilina (Theophylline Ethylenediamine) is strictly defined by regulatory documents based on age, underlying health conditions, and drug sensitivity.

Absolute Contraindications

Use of this medicine is contraindicated (must not be used) in patients with known hypersensitivity to theophylline, ethylenediamine, or any other related xanthine derivative. Absolute non-eligibility also applies to infants under six months of age, and individuals diagnosed with active peptic ulcer disease or an underlying seizure disorder.

Restricted and Conditional Use

Use requires caution and close monitoring in several populations due to reduced drug clearance, which increases the risk of toxicity. This includes older adults (over 60 years) and patients with liver disease (e.g., cirrhosis), congestive heart failure, cor pulmonale, hypothyroidism, or severe infection. Conditional eligibility also applies to individuals with a fever of 102°F or higher or those who recently ceased smoking.

Pregnancy and Lactation Status

Aminofilina is classified as FDA Pregnancy Category C, meaning its use during pregnancy is not recommended unless clearly necessary. The drug is known to be excreted into human milk, and official labeling advises that nursing infants should be observed for potential pharmacological effects.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Aminofilina (Theophylline) interactions is defined by specific drug combinations that alter its clearance or systemic effects. Co-administration with other xanthine derivatives is formally prohibited due to the significantly increased risk of systemic toxicity. Certain medicinal products are classified as metabolic inhibitors because they decrease Theophylline clearance through CYP enzyme inhibition; these include Quinolone antibiotics (e.g., ciprofloxacin), Macrolide antibiotics (e.g., erythromycin), Cimetidine, and Fluvoxamine, all of which formally lead to increased drug exposure. Conversely, metabolic inducers like Rifampicin and certain anticonvulsants (e.g., phenytoin) are documented to increase clearance, decreasing exposure.

Pharmacodynamic interactions are also documented. Co-administration with Sympathomimetics carries the risk of synergistic toxicity, and Theophylline formally antagonizes the therapeutic effect of Adenosine. Administration also has specific procedural constraints: for patients using enteral tube feedings, patient advice suggests interrupting the feeding for one hour before and one hour after the dose.

Interactions extend to consumer products: Tobacco smoking and the herbal product St. John’s Wort are listed as substances that increase clearance, while a single large dose of alcohol is documented to decrease clearance. Specific population constraints exist, as clearance is formally reduced in the elderly, patients with hepatic impairment, and in the presence of high fever, conditions that amplify the risk associated with all interacting medicines.

Mechanism of Action

Enzyme Inhibition and Airway Smooth Muscle Relaxation

The primary action of Aminofilina's active component, theophylline, is through the non-selective competitive inhibition of specific phosphodiesterase (PDE) enzymes, primarily PDE3 and PDE4. This molecular blockade prevents the rapid breakdown of the key intracellular messenger, cyclic AMP (cAMP), leading to its accumulation. The elevated cAMP levels in the bronchial tubes trigger a cascade that directly causes relaxation of the airway smooth muscle, resulting in a widening of the air passages (bronchodilation).

Antagonism of Extracellular Adenosine Receptors

Theophylline simultaneously acts as a non-selective competitive antagonist at adenosine receptors (A1, A2, A3) located throughout the body. By blocking these receptors, the drug counteracts the natural effects of adenosine, which include promoting bronchoconstriction and inhibitory CNS activity. This action helps to enhance the contractility of the diaphragm and other respiratory muscles while providing central nervous system stimulation that contributes to increased central respiratory drive.

Molecular Modulation of Airway Inflammation

In addition to the smooth muscle effects, the mechanism of theophylline involves the indirect activation and stabilization of Histone Deacetylase 2 (HDAC2). By restoring HDAC2 function, the drug helps the cell's nuclear machinery suppress the activity of the pro-inflammatory transcription factor, NF-κB. This mechanism leads to the attenuation of pro-inflammatory gene expression within airway cells.

Dosage and Administration Information

How to Use Aminofilina

The usage of Aminofilina (Theophylline ethylenediamine) is strictly governed by administration protocols that define the route, dosage calculation, and monitoring requirements. These instructions ensure the active component, theophylline, is maintained within its narrow therapeutic range, as clearance can vary significantly among individuals.

Administration Routes and Standard Regimens

The selection of the administration route depends on the patient's clinical situation, with Intravenous (IV) use reserved for acute management and Oral formulations used for long-term control of symptoms.

Feature	Official Labeled Instruction
IV Loading Dose	Calculated as 5.7 mg/kg of Aminofilina (based on ideal body weight) and administered slowly over at least 30 minutes in a supervised setting.
Oral Schedule	Typically multiple times daily, such as every 6 to 8 hours, for maintenance. Immediate-release forms should be taken on an empty stomach (1 hour before or 2 hours after a meal).

Dosing Adjustment and Monitoring

All dosing is highly individualized and relies on frequent Therapeutic Drug Monitoring (TDM). The primary goal is to maintain the serum theophylline concentration between 10 to 20 mcg/mL.

Clearance-Dependent Adjustment: The maintenance dose or IV infusion rate must be reduced for older adults (age 60 years and older) and in patients with conditions that impair clearance, such as hepatic disease or cardiac decompensation.
Tablet Handling: Extended-release tablets must be swallowed whole and must not be crushed or chewed, as altering the formulation compromises its release mechanism.

These protocols ensure a systematic framework for administration, emphasizing calculated dosage based on body weight and strict monitoring to achieve the required concentration.

Recent Clinical Evidence

Research exploring Aminofilina has focused on Randomized Controlled Trials (RCTs) and Systematic Reviews for both adults and children with severe, acute episodes of airway tightening. These studies monitored short-term outcomes such as airflow metrics, length of hospital stay, and need for intensive care. When the drug was studied for addition to current standard medications, findings were mixed regarding whether its use was associated with further differences in these important clinical outcomes. Evidence is limited and heterogeneous, as many foundational trials are older.

For Chronic Obstructive Pulmonary Disease (COPD), Controlled Trials and Observational Studies have examined the drug's role in long-term management, monitoring respiratory function values and exacerbation frequency. Studies reported measured differences in function during observation, but evidence regarding consistent long-term outcomes remains limited. In Apnea of Prematurity (AOP) in preterm infants, Comparative Trials monitored the incidence of breathing interruptions and ventilatory support. Research reported that use was associated with differences in apnea frequency, but findings were mixed when evaluated alongside alternative methylxanthine treatments.

Because the overall evidence landscape shows that follow-up durations were limited in many studies, long-term effects are not fully established. Data for certain patient groups, such as older adults, remain insufficient, and research exploring whether the drug's use provides further advantages when combined with current standard care is an area where inconsistent findings were reported, highlighting where more research is necessary.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Aminofilina (FAQ)

Q: How quickly does Aminofilina start to work?

A: According to official product information, the speed of action depends on the form used. Immediate-release oral forms are absorbed rapidly, and their action typically begins within 1 to 2 hours. The intravenous form, typically administered for acute management, is documented to begin its action within 30 minutes.

Q: How long do the effects of Aminofilina last?

A: The duration of the drug's effects is highly variable from person to person. In healthy, non-smoking adults, the average elimination half-life is around 8 to 9 hours, according to pharmacokinetics data. Extended-release formulations are designed to maintain therapeutic levels for up to 12 hours.

Q: Does taking Aminofilina with a meal change how it works?

A: Official information indicates that for immediate-release forms, taking the medicine with food is not expected to cause a clinically significant change in how it is absorbed. However, with some extended-release tablets, taking the drug alongside a meal may delay the time it takes to reach peak levels in the blood.

Q: What happens if I miss a scheduled dose of Aminofilina?

A: Official patient guidance advises against taking a double dose to make up for a missed dose, as accidentally taking the wrong amount can be harmful. Official guidance emphasizes the importance of consulting with a healthcare professional regarding any concerns about a missed dose.

Q: Are antibiotics known to interact with Aminofilina?

A: Yes, regulatory documents list specific types of antibiotics, such as quinolones and macrolides, as interacting with Aminofilina. These medicines are documented to decrease the drug's clearance, which may lead to elevated blood concentrations and a potential increase in adverse effects.

Q: Does smoking affect how Aminofilina works in the body?

A: Yes, tobacco smoke is officially documented as increasing the rate at which the body clears the drug. This effect typically results in lower Aminofilina levels in the blood. The rate of clearance is an important factor considered during individualized prescribing and monitoring.

Q: Is Aminofilina ever used for sudden, severe breathing difficulty?

A: The intravenous (IV) formulation is officially reserved for the acute management of severe symptoms and reversible airflow obstruction. The intravenous formulation is documented for use in a supervised setting to treat acute episodes of reversible airflow obstruction.

Q: Why is Aminofilina sometimes given in a hospital setting?

A: The drug is sometimes administered in a hospital setting when the intravenous form is used for acute management of severe breathing issues. This IV use requires careful calculation and slow infusion in a supervised environment due to the drug's narrow therapeutic range.

Q: What are the signs that Aminofilina is working correctly?

A: Clinical efficacy is generally associated with maintaining a serum concentration above 10 mcg/mL, a level considered relevant to the drug's intended action on pulmonary function. This concentration is associated with improvement in symptom control.

Q: Is it normal to feel a bit restless when starting Aminofilina?

A: Restlessness is officially listed as one of the commonly reported side effects, as the medicine has stimulant properties on the nervous system. Like other adverse effects, restlessness is often linked to the concentration of the drug in the blood.

Q: Is Aminofilina the same as Theophylline?

A: No, Aminofilina is a combination substance, or a drug salt, that is made up of two parts. The pharmacologically active component is Theophylline, and the second part is a stabilizing agent called ethylenediamine.

Q: Can other common prescription medications affect Aminofilina levels in the body?

A: Yes, a number of other prescription medications are documented to alter the levels of Aminofilina in the body. These include certain anti-ulcer drugs and some anticonvulsants, which may speed up or slow down the drug's clearance rate.

Q: Is Aminofilina safe for use in children?

A: Official dosing guidelines are established and available for children and adolescents starting from one year of age. However, the drug is formally contraindicated in infants under six months of age.

Q: Can Aminofilina be used during pregnancy?

A: The medicine is classified as FDA Pregnancy Category C. Regulatory information states that use during pregnancy should be considered only when the potential benefit is determined to justify the potential risk to the fetus.

Q: Does Aminofilina interact with caffeine?

A: Yes, excessive consumption of caffeine is documented to potentially increase theophylline blood levels. Since both are stimulants, consuming too much caffeine may add to existing side effects such as insomnia, nervousness, or a rapid heart rate.

Q: What types of breathing problems does this drug help with?

A: Theophylline is indicated for the treatment of symptoms and reversible airflow obstruction associated with chronic lung diseases. These conditions include chronic asthma, chronic bronchitis, and emphysema.

Q: Why do doctors use Aminofilina instead of other bronchodilators?

A: The drug is documented to have two distinct types of action. It causes smooth muscle relaxation, which is the definition of a bronchodilator, but it also has non-bronchodilator effects that suppress the airway’s response to various stimuli.

Q: Is there a generic version of Aminofilina available?

A: Yes, the active component, Theophylline, is marketed under an Abbreviated New Drug Application (ANDA) status, which means that generic formulations are manufactured and distributed by multiple pharmaceutical companies.

Q: Does the form of the drug (tablet, injection) affect its action?

A: Yes, the route of administration affects the speed of action. The intravenous form, used in acute settings, is designed to reach its peak concentration much faster than the oral tablet or solution.

Q: Is there any evidence about Aminofilina for conditions other than asthma?

A: Yes, the medicine is officially indicated for other chronic lung diseases such as emphysema and chronic bronchitis. Additionally, dosing guidelines are established for the use of the drug in specific patient populations, such as those with Apnea of Prematurity.

Q: What are the risks of using Aminofilina long-term?

A: Regulatory documents emphasize that the primary consideration during long-term therapy is the risk associated with elevated blood concentrations. For this reason, official documentation advises that serum levels be monitored periodically, such as every 6–12 months, to keep the drug within its proper therapeutic range.

Q: Can I drive or operate machinery while taking Aminofilina?

A: Official documentation notes the potential for nervous system side effects, such as headaches, confusion, tremor, or seizures. These effects are officially documented as potential adverse reactions that may impact physical and cognitive abilities.

Q: Does Aminofilina cause changes in mood or anxiety?

A: The drug is a Central Nervous System (CNS) stimulant, and official documentation indicates that CNS stimulants can potentially cause psychotic symptoms or exacerbate existing behavior disturbances or thought disorders.

Q: What are the restrictions on activities while taking this medicine?

A: Documented restrictions relate to substances that alter the drug's metabolism. These include limiting or avoiding the consumption of tobacco products and excessive caffeine, as both can significantly change the level of the drug in the blood.

Q: Why must I tell my doctor about all other supplements I take with Aminofilina?

A: Official regulatory patient information advises informing a healthcare professional about all other medicines, vitamins, and herbal products (like St. John’s Wort). This is because these substances can significantly affect how Aminofilina works or change its safety profile.

Q: What should I do if I experience a mild side effect?

A: Patient guidance advises consulting a healthcare professional, such as a doctor, nurse, or pharmacist, if there are concerns about how the patient is feeling or if a side effect is experienced.

How should Aminofilina be stored and disposed of?

How to Store and Dispose of Aminophylline (Aminofilina)

Aminophylline must be stored under specific environmental conditions to ensure its stability, as mandated by regulatory labeling. The product is required to be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), and must be protected from freezing. Certain oral formulations may require storage below 30 C.

The medicine should be kept in its original container and must always be stored out of the reach and sight of children. If the injection solution is diluted, it has a limited stability period, generally 24 hours at room temperature or 48 hours under refrigeration.

For disposal, unused or expired Aminophylline must be handled according to local pharmaceutical waste requirements. Household disposal guidelines stipulate that the product must not be poured down a sink or toilet (wastewater system).

Aminofilina